Detection Beyond Diagnostics
Navaux is a life science company with a focus on early cancer diagnostics. The company has developed several novel, non-invasive assays capable of detecting circulating levels of key proteins in the blood linked to a variety of disease states such as cancer and dementia. Hepsin, for example has been extensively cited in both preclinical and clinical literature (> 500 publications) as a cancer-associated molecule involved in the very earliest stages of cancer development as well as progression to metastatic disease. Using our proprietary technology, circulating hepsin levels can be evaluated quantitatively in real-time, thus providing physicians with biologically relevant insight into the possibility of early tumor formation. In doing so, our technology provides a unique avenue for the detection of cancer prior to the appearance of clinical symptoms.
With the advent of direct-to-consumer genetic testing, consumers now have unprecedented access to predictive information that, in many instances, raises awareness regarding their potential to develop devastating cancers. Regrettably, a void still exists in providing those same individuals, and many others with a known family history of cancer, with a non-invasive, quantitative assay capable of detecting an early cancer event actively occurring in the body. Navaux is uniquely positioned to fill this void by offering patients easy access to an affordable external lab test capable of detecting cancer in its earliest stages. Stemming from this early intervention at the PCP level, patients and physicians alike are empowered to seek very early avenues of clinical intervention.
The Future and Broader Impact
Navaux is currently pursuing R&D though our pipeline of discoveries that will have major impact on the following disease states: